X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DIVIS LABORATORIES ALEMBIC PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 16.7 32.9 50.7% View Chart
P/BV x 3.6 7.4 49.1% View Chart
Dividend Yield % 1.0 0.6 173.2%  

Financials

 ALEMBIC PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
DIVIS LABORATORIES
Mar-18
ALEMBIC PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6641,142 58.2%   
Low Rs412533 77.4%   
Sales per share (Unadj.) Rs208.7146.6 142.4%  
Earnings per share (Unadj.) Rs31.033.0 93.8%  
Cash flow per share (Unadj.) Rs37.138.4 96.6%  
Dividends per share (Unadj.) Rs5.5010.00 55.0%  
Dividend yield (eoy) %1.01.2 85.6%  
Book value per share (Unadj.) Rs144.2222.8 64.7%  
Shares outstanding (eoy) m188.52265.47 71.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.65.7 45.1%   
Avg P/E ratio x17.425.3 68.5%  
P/CF ratio (eoy) x14.521.8 66.5%  
Price / Book Value ratio x3.73.8 99.3%  
Dividend payout %17.730.3 58.6%   
Avg Mkt Cap Rs m101,461222,318 45.6%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m7,4674,561 163.7%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m39,34738,915 101.1%  
Other income Rs m941,134 8.3%   
Total revenues Rs m39,44140,049 98.5%   
Gross profit Rs m8,73612,617 69.2%  
Depreciation Rs m1,1521,425 80.9%   
Interest Rs m18413 1,384.2%   
Profit before tax Rs m7,49312,313 60.9%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5683,543 44.2%   
Profit after tax Rs m5,8448,770 66.6%  
Gross profit margin %22.232.4 68.5%  
Effective tax rate %20.928.8 72.7%   
Net profit margin %14.922.5 65.9%  
BALANCE SHEET DATA
Current assets Rs m19,57745,351 43.2%   
Current liabilities Rs m14,8966,507 228.9%   
Net working cap to sales %11.999.8 11.9%  
Current ratio x1.37.0 18.9%  
Inventory Days Days90127 70.8%  
Debtors Days Days4595 47.7%  
Net fixed assets Rs m27,09721,160 128.1%   
Share capital Rs m377531 71.0%   
"Free" reserves Rs m26,81158,625 45.7%   
Net worth Rs m27,18859,156 46.0%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77867,832 70.4%  
Interest coverage x41.7926.8 4.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 143.5%   
Return on assets %12.612.9 97.4%  
Return on equity %21.514.8 145.0%  
Return on capital %23.620.8 113.3%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m19,45332,359 60.1%   
Fx outflow Rs m6,0659,042 67.1%   
Net fx Rs m13,38823,317 57.4%   
CASH FLOW
From Operations Rs m8,1207,759 104.7%  
From Investments Rs m-7,556-4,783 158.0%  
From Financial Activity Rs m590-3,142 -18.8%  
Net Cashflow Rs m1,153-166 -694.8%  

Share Holding

Indian Promoters % 74.1 52.0 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 11.8 24.6%  
FIIs % 9.1 19.0 47.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.2 80.8%  
Shareholders   49,328 31,796 155.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALKEM LABORATORIES  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON   

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jalan Committee Recommendations; US-China Trade Worries; Key Q1FY20 Results and Top Stocks in Action(Pre-Open)

On Thursday, the Indian share markets fell sharply in late trade as US-China trade worries dragged global peers.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 09:19 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS